Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1B1 | P15121 | 2/20 | 0.49 |
| ▸ | IDO1 | P14902 | 2/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.44 |
| ▸ | POLQ | O75417 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 3/20 | 0.41 |
| ▸ | AR | P10275 | 1/20 | 0.41 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 2/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2879992 | 0.98 | AKR1B1 (0.50) | AKR1B1IDO1NPSR1POLQKDM4E | |
| SCHEMBL2880351 | 0.96 | AKR1B1 (0.49) | AKR1B1IDO1NPSR1POLQKDM4E | |
| SCHEMBL2903946 | 0.82 | P2RX7 (0.43) | — | |
| SCHEMBL4002424 | 0.81 | TAAR1 (0.38) | AKR1B1ALDH1A1KMT2AGAA | |
| SCHEMBL18240882 | 0.80 | IDO1 (0.44) | AKR1B1IDO1NPSR1POLQKDM4E | |
| SCHEMBL7787225 | 0.79 | CA2 (0.43) | AKR1B1NPSR1ALDH1A1TDP1RECQL | |
| SCHEMBL514294 | 0.79 | AKR1B1 (0.50) | AKR1B1IDO1NPSR1POLQKDM4E | |
| SCHEMBL2880348 | 0.79 | AKR1B1 (0.50) | AKR1B1IDO1NPSR1POLQKDM4E | |
| SCHEMBL31405393 | 0.79 | AKR1B1 (0.50) | AKR1B1IDO1NPSR1POLQKDM4E | |
| SCHEMBL514295 | 0.79 | NPSR1 (0.53) | AKR1B1IDO1NPSR1POLQKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8283373-B2 | Inhibitors of cytosolic phospholipase A2 | PFIZER INC. (US) | 2012-10-09 | — | — | US | disclosed |
| EP-1891006-B1 | INHIBITORS OF CYTOSOLIC PHOSPHOLIPASE A2 | WYETH LLC (US) | 2010-11-24 | — | — | EP | disclosed |
| EP-2248801-A1 | Inhibitors of cytosolic phospholipase a2 | Wyeth LLC (US) | 2010-11-10 | — | — | EP | disclosed |
| US-20100029645-A1 | Inhibitors of Cytosolic Phospholipase A2 | WYETH LLC | 2010-02-04 | — | — | US | disclosed |
| US-20100022536-A1 | Inhibitors of Cytosolic Phospholipase A2 | NOVARTIS AG (CH) | 2010-01-28 | — | — | US | disclosed |
| US-7557135-B2 | Inhibitors of cytosolic phospholipase A2 | WYETH (US) | 2009-07-07 | — | — | US | disclosed |
| EP-1718605-B1 | PROCESSES FOR THE PREPARATION OF ARYL-AND HETEROARYL-ALKYLSULFONYL HALIDES | WYETH CORP (US) | 2009-06-17 | — | — | EP | disclosed |
| EP-1891006-A2 | INHIBITORS OF CYTOSOLIC PHOSPHOLIPASE A2 | Wyeth a Corporation of the State of Delaware (US) | 2008-02-27 | — | — | EP | disclosed |
| US-7321061-B2 | Processes for the preparation of aryl- and heteroaryl-alkylsulfonyl halides | WYETH (US) | 2008-01-22 | — | — | US | disclosed |
| US-20070004719-A1 | Inhibitors of cytosolic phospholipase A2 | WYETH (US) | 2007-01-04 | — | — | US | disclosed |
| WO-2006128142-A2 | INHIBITORS OF CYTOSOLIC PHOSPHOLIPASE A2 | WYETH (US) | 2006-11-30 | — | — | WO | disclosed |
| EP-1718605-A1 | PROCESSES FOR THE PREPARATION OF ARYL-AND HETEROARYL-ALKYLSULFONYL HALIDES | Wyeth (US) | 2006-11-08 | — | — | EP | disclosed |
| WO-2005082843-A1 | PROCESSES FOR THE PREPARATION OF ARYL-AND HETEROARYL-ALKYLSULFONYL HALIDES | WYETH (US) | 2005-09-09 | — | — | WO | disclosed |
| US-20050187408-A1 | Processes for the preparation of aryl-and heteroaryl-alkylsulfonyl halides | WYETH (US) | 2005-08-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100022536-A1 | Inhibitors of Cytosolic Phospholipase A2 | PLA2G4B, PLA2G4A, PLA2G12A | AKR1B1 1698/4885IDO1 851/4885NPSR1 3332/4885 |
| US-20050187408-A1 | Processes for the preparation of aryl-and heteroaryl-alkylsulfonyl halides | ARSA, AHR, STS | AKR1B1 390/4885IDO1 832/4885NPSR1 113/4885 |
| US-20100029645-A1 | Inhibitors of Cytosolic Phospholipase A2 | PLA2G4B, PLA2G4A, PLA2G12A | AKR1B1 1698/4885IDO1 851/4885NPSR1 3332/4885 |
| US-20070004719-A1 | Inhibitors of cytosolic phospholipase A2 | PLA2G4B, PLA2G4A, PLA2G12A | AKR1B1 1698/4885IDO1 851/4885NPSR1 3332/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.